ESH MM 2018 | Update on recent smoldering multiple myeloma trials
Clinical trials in smoldering multiple myeloma (SMM) have produce many exciting results, with new drug approvals and standards of care arising from recent studies. We got an update on the latest SMM trials from Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. Dr Mateos explains how there are more than 50 such trials ongoing currently, which are typically lenalidomide-dexemethasone based with the addition of a novel agent such as elotuzumab or ixazomib. She also describes a daratumumab-based study with curative intent that is running.
Get great new content delivered to your inboxSign up